Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Altrenogest is a synthetic steroidal progestin used primarily in veterinary medicine to suppress or synchronize estrus (heat) in female horses (mares) and pigs (gilts)[3][4][5]. It is structurally related to trenbolone and acts as an agonist of the progesterone receptor. By binding to these receptors and mimicking the effects of endogenous progesterone[6], altrenogest inhibits the secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus. This leads to reduced release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), preventing ovulation and stabilizing the uterine lining[6][8]. The drug is administered orally as a solution for horses or mixed with feed for pigs. Its main indications are suppression of estrus for breeding management or performance scheduling in mares and synchronization of estrus in gilts[1][2][4]. Altrenogest is approved only for veterinary use; it is not indicated for human use due to potential health risks upon exposure[4]. It has been marketed since the early 1980s under various brand names depending on species and region.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on altrenogest.